In re application of

Karl-Hermann SCHLINGENSIEPEN, et al.

Appln. No.:

10/591,048

Page - 4 -

REMARKS

The drawings have been amended to add Figure 1, which was inadvertently omitted, and the drawings have been renumbered to reflect the addition of Figure 1. Figure 1 is described in the text of the specification, paragraph [000103]. No new matter has been added. Paragraph

[000103] recites:

Figure 1 shows the inhibition of prostate cancer cell Line PC-3.

The upper two Squares indicate the migration of the control group

incubated only with Lipofectin. The two Squares below clearly show

reduced migration of cells incubated with Lipofectin and the antisense

oligonucleotide identified in the Sequence listing with Seq. Id. No. 14.

The two Squares left hand show the starting conditions. The two

Squares at the right hand show the migration after 24 hours, which was

clearly inhibited. This indicates a reduced formation of metastases.

The specification has been amended to accurately reflect the priority data as shown on the

declaration and on the front page of the publication WO 2005/084712 of priority document

PCT/EP2005/002101.

Entry and favorable consideration prior to examination are respectfully requested. Please

charge any shortage in fees and credit any excess fees due in connection with this application to

Deposit Account 500951.

Respectfully submitted,

AKERMAN SENTERFITT

Date: 1/25/08

Stephan A. Pendorf

Registration No. 32,665

222 Lakeview Ave., Suite 400

West Palm Beach, FL 33401-6147

(561) 653-5000

4